ESMO 2024: Focus on Liver Cancer

Brandon TwyfordGI Cancer | March 19, 2025

The LEAP-012 study showed improved progression-free survival with lenvatinib, pembrolizumab, and TACE in HCC.

Zev Wainberg, MD, MScGastric Cancer | March 19, 2025

Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.

Josep M. Llovet, MDGI Cancer | March 19, 2025

Dr. Josep Llovet discusses promising data, including higher PFS and OS, in metastatic liver cancer from the LEAP-012 trial.

Zachary BessetteGI Cancer | March 19, 2025

STRIDE shows “unprecedented” 5-year survival benefit, with no additional serious safety events, for patients with uHCC.

Zachary BessetteGI Cancer | March 19, 2025

A phase 2 trial comparing DEB-TACE with irinotecan, mitomycin C vs DEB-TACE with doxorubicin for intermediate-stage HCC.

Zachary BessetteGI Cancer | March 19, 2025

FOLFOX-HAIC plus sintilimab and IBI305 demonstrates promising safety and efficacy in uHCC, Child-Pugh B liver function.